Last reviewed · How we verify

Air Liquide Santé International — Portfolio Competitive Intelligence Brief

Air Liquide Santé International pipeline: 3 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Kalinox 170 bar Kalinox 170 bar marketed
sévoflurane sévoflurane marketed
Mix of 50% oxygen and 50% nitrogen Mix of 50% oxygen and 50% nitrogen marketed Medical gas Respiratory/Anesthesia
EMONO EMONO phase 3 Therapeutic gas Critical Care / Pulmonary
Air/Oxygen Air/Oxygen phase 3 Medical gas Respiratory / Critical Care

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Central Denmark Region · 1 shared drug class
  2. University of South Florida · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Air Liquide Santé International:

Cite this brief

Drug Landscape (2026). Air Liquide Santé International — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/air-liquide-sant-international. Accessed 2026-05-17.

Related